Quick Answer
Arcus Biosciences, Inc. reported Stockholders Equity of $631.00 million for fiscal year 2025.
Arcus Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $631.00M | +30.1% |
| 2024 | $485.00M | +5.0% |
| 2023 | $462.00M | -29.7% |
| 2022 | $657.00M | -22.0% |
| 2021 | $842.00M | +67.7% |
| 2020 | $502.00M | +206.1% |
| 2019 | $164.00M | -30.2% |
| 2018 | $234.94M | +424.8% |
| 2017 | -$72.33M | -261.7% |
| 2016 | -$19.99M | -821.0% |
| 2015 | -$2.17M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $436.00M | -22.8% | -20.6% |
| June 30, 2025 | $549.00M | -13.5% | +3.4% |
| March 31, 2025 | $531.00M | -24.9% | +9.5% |
| December 31, 2024 | $485.00M | +5.0% | -14.2% |
| September 30, 2024 | $565.00M | +8.7% | -11.0% |
| June 30, 2024 | $635.00M | +12.2% | -10.2% |
| March 31, 2024 | $707.00M | +17.8% | +53.0% |
| December 31, 2023 | $462.00M | -29.7% | -11.2% |
- Arcus Biosciences, Inc. showed an increase of +30.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2015–2025 period, Arcus Biosciences, Inc.’s stockholders equity has grown by 29164.9% (from -$2.17 million to $631.00 million).
- The most recent figure is from Arcus Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: